Literature DB >> 25063010

The influence of sentinel lymph node biopsy on survival for intermediate-thickness melanoma.

Swapnil D Kachare1, Jason Brinkley, Jan H Wong, Nasreen A Vohra, Emmanuel E Zervos, Timothy L Fitzgerald.   

Abstract

BACKGROUND: The Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) failed to demonstrate a survival advantage for sentinel lymph node biopsy (SNB) in melanoma. This may have been secondary to inadequate statistical power. This study was designed to determine the impact of SNB on melanoma-specific survival (MSS) in a larger patient cohort.
METHODS: From 2003-2008, patients with tumors 1-4 mm in thickness and clinically negative nodes were identified within the SEER registry. Propensity score was used to create two matched cohorts: those who underwent a wide excision with SNB or wide excision alone. RESULT: A total of 15,274 met inclusion criteria and 7,910 comprised the match cohort. Average age was 67.4 years. The majority were male (62.3 %) and white (97.2 %). Primary tumors were most frequently nonulcerated (77.1 %), located on the extremity (42.3 %), and T2 (64.1 %). There were 3,955 patients in both the SNB and observation groups. There was no significant difference in gender, ethnicity, ulceration status, primary site, or T-classification between the groups. Improved 5-year MSS was associated with SNB (85.7 vs. 84.0 %), female gender (88.3 vs. 82.7 %), absence of ulceration (87.5 vs. 75.7 %), extremity location (87.4 %), T2 disease (88.6 vs. 77.9 %), and a negative SNB (88.9 vs. 64.8 %). The relationships between observation [hazard ratio (HR) 1.18], male gender (HR 1.33), ulceration (HR 1.77), head-and-neck location (HR 1.34), and T3 disease (HR 1.82) persisted on multivariate analysis.
CONCLUSIONS: Status of the sentinel node is the strongest predictor of survival in patients with intermediate thickness melanoma. SNB compared with observation was associated with a modest survival advantage.

Entities:  

Mesh:

Year:  2014        PMID: 25063010     DOI: 10.1245/s10434-014-3954-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Minimally invasive follicular carcinoma: predictors of vascular invasion and impact on patterns of care.

Authors:  Paolo Goffredo; Christa Jillard; Samantha Thomas; Randall P Scheri; Julie Ann Sosa; Sanziana Roman
Journal:  Endocrine       Date:  2015-06-16       Impact factor: 3.633

2.  Melanoma nodal management in Ontario the year after the 2012 American Society of Clinical Oncology and Society of Surgical Oncology guideline.

Authors:  S Latosinsky; B Allen; S Z Shariff
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

3.  Stratifying SLN incidence in intermediate thickness melanoma patients.

Authors:  James M Chang; Heidi E Kosiorek; Amylou C Dueck; Stanley P L Leong; John T Vetto; Richard L White; Eli Avisar; Vernon K Sondak; Jane L Messina; Jonathan S Zager; Carlos Garberoglio; Mohammed Kashani-Sabet; Barbara A Pockaj
Journal:  Am J Surg       Date:  2017-12-14       Impact factor: 2.565

4.  Head & neck melanoma: A 22-year experience of recurrence following sentinel lymph node biopsy.

Authors:  Kristen A Echanique; Shabnam Ghazizadeh; Andy Moon; Kera Kwan; Peter A Pellionisz; Dennis Rünger; David Elashoff; Maie St John
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-06-21

5.  Sentinel lymph node biopsy is a prognostic measure in pediatric melanoma.

Authors:  Jina Kim; Zhifei Sun; Brian C Gulack; Mohamed A Adam; Paul J Mosca; Henry E Rice; Elisabeth T Tracy
Journal:  J Pediatr Surg       Date:  2016-03-04       Impact factor: 2.545

Review 6.  Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma.

Authors:  Alberto Falk Delgado; Sayid Zommorodi; Anna Falk Delgado
Journal:  Curr Oncol Rep       Date:  2019-04-26       Impact factor: 5.075

7.  Racial Differences in the Prognosis and Survival of Cutaneous Melanoma From 1990 to 2020 in North America: A Systematic Review and Meta-Analysis.

Authors:  Megan Lam; Jie Wei Zhu; Angie Hu; Jennifer Beecker
Journal:  J Cutan Med Surg       Date:  2021-10-22       Impact factor: 2.092

Review 8.  Sentinel lymph node biopsy in melanoma: beyond histologic factors.

Authors:  Michael J Carr; Federico A Monzon; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2021-06-08       Impact factor: 5.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.